Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR-Inhibitors

Abstract

Methods of treating symptoms of skin disorders with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in pruritis, xerosis, or other skin disorder-affected function. Skin disorders upon which the methods of the invention can improve symptoms and causes of the disorders include eczema, bullous pemphigoid, atopic dermatitis, and psoriasis.

Description

I. CROSS-REFERENCE TO RELATED APPLICATION[0001]Pursuant to 35 U.S.C. § 119 (e), this application claims priority to the filing date of U.S. Provisional Patent Application No. 62 / 572,251, filed Oct. 13, 2017; the disclosure of which application is herein incorporated by reference.II. FIELD OF THE INVENTION[0002]This invention pertains to the prevention and treatment of skin disorders, e.g. pruritis and xerosis and associated disease. In particular, the invention relates to the use of CCR3 modulating agents, such as CCR3 inhibitors, to treat and / or prevent disorders associated with the skin.III. INTRODUCTION[0003]The following is offered as background information only and is not admitted being prior art to the present invention.[0004]Eosinophil-associated rare diseases are a group of uncommon conditions in which eosinophil leukocytes play a critical pathophysiological role. The skin is one site at which eosinophils can become pathologically upregulated, contributing to a broad spectru...

AI Technical Summary

Benefits of technology

The present invention provides compounds that target the root cause of pruritis, xerosis, and associated diseases, rather than just treating symptoms. These compounds act as antagonists of c-c motif chemokine receptor 3 (CCR3), which is a receptor for eotaxin-1. Eotaxin-1 is a protein that is increased in levels in blood plasma with aging, which is one of the factors implicated with increased pruritis and xerosis. The compounds can be administered systemically and can also be formulated into a topical agent for immediate relief of symptoms. The methods of treating patients include treating symptoms associated with dermatologic diseases, systemic diseases, and endocrine disorders, among others. The compounds can improve skin dryness and cessation of scratching due to itch.

Problems solved by technology

Oral corticosteroids at high doses are poorly tolerated particularly in the elderly however.

Additionally, oral corticosteroids may contribute to high rates of mortality.

And topical corticosteroids must be administered over the entire body with wraps, increasing burden on patients and caregivers as well as reducing compliance.

This lack of eosinophil contribution along with the relative brevity (a few days on the whole) of those mouse models do not provide an appropriate pre-clinical tool to investigate BP per se.

Additionally, these current treatments have exhibited limitations such as unwanted side effects, drug tolerance, and limited efficacy.

Images